The Zhitong Finance App learned that J.P. Morgan Chase's latest research report said that the Imdelltra first-line maintenance treatment data announced by Amgen (AMGN.US) at the ESMO conference last weekend was “impressive”, or may support the drug's advance towards an earlier treatment line, making it a potentially 5 billion dollar blockbuster product. However, the bank still maintains a “neutral” rating, with a target price of $350, which is lower than the current stock price of about $439.

The Zhitong Finance App learned that J.P. Morgan Chase's latest research report said that the Imdelltra first-line maintenance treatment data announced by Amgen (AMGN.US) at the ESMO conference last weekend was “impressive”, or may support the drug's advance towards an earlier treatment line, making it a potentially 5 billion dollar blockbuster product. However, the bank still maintains a “neutral” rating, with a target price of $350, which is lower than the current stock price of about $439.